A cost‐effectiveness analysis of preimplantation genetic testing for aneuploidy (<scp>PGT</scp>‐A) for up to three complete assisted reproductive technology cycles in women of advanced maternal age

Abstract

This is the first study to use real-world patient-level data to assess the cost-effectiveness of PGT-A in older women from the healthcare and patient perspectives. The findings contribute to the ongoing debate on the role of PGT-A in clinical practice.